Physician profile
John D Gary
NPI 1902827819
$1,982.43
in general payments reported to CMS, 2019-2025
21 companies · $84.50 in 2025
The $84.50 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $419 · 2021: $273 · 2022: $158 · 2023: $155 · 2024: $453 · 2025: $84.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655 · Travel and Lodging: $38.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.66 |
| Travel and Lodging | $38.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $530.63 | 2019-2025 | Smartvest |
| Glaxosmithkline, LLC. | $418.24 | 2019-2024 | Nucala, Trelegy Ellipta |
| Philips North America LLC | $132.16 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $117.85 | 2023-2024 | Xywav |
| Ethicon INC. | $116.96 | 2020-2024 | Monarch Platform |
| Actelion Pharmaceuticals US, INC. | $112.84 | 2019-2022 | |
| Medical Device Business Services, INC. | $96.08 | 2024 | Monarch |
| Allergan, INC. | $92.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $58.77 | 2021-2023 | Dupixent |
| Olympus America INC. | $55.62 | 2020 | |
| Pulmonx Corporation | $47.61 | 2022-2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $46.30 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $27.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $21.51 | 2021 | |
| Genzyme Corporation | $19.48 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $17.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.64 | 2019 | |
| Siemens Medical Solutions USA, INC. | $15.70 | 2023 | Cerianna |
| Abbvie INC. | $13.63 | 2023 | |
| Mallinckrodt Enterprises LLC | $12.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.